Institution
University of Groningen
Education•Groningen, Groningen, Netherlands•
About: University of Groningen is a education organization based out in Groningen, Groningen, Netherlands. It is known for research contribution in the topics: Population & Poison control. The organization has 36346 authors who have published 69116 publications receiving 2940370 citations. The organization is also known as: Rijksuniversiteit Groningen & RUG.
Papers published on a yearly basis
Papers
More filters
TL;DR: In this article, the authors examined factors influencing the acceptability of energy policies aimed to reduce the emission of CO 2 by households and found that personal norms mediated the relationship between AR and acceptability judgements.
894 citations
Queen Mary University of London1, University of Groningen2, Utrecht University3, University of Debrecen4, National Institutes of Health5, University of Milan6, University Medical Center Utrecht7, Hungarian Academy of Sciences8, Casa Sollievo della Sofferenza9, King's College London10, Wellcome Trust Sanger Institute11, University of Tampere12, Trinity College, Dublin13, Mater Misericordiae University Hospital14, Sapienza University of Rome15, Leiden University16, Mayo Clinic17, University of California, Los Angeles18, University of Helsinki19, University of Naples Federico II20, Beckman Research Institute21, University of Milano-Bicocca22
TL;DR: This article performed a second-generation genome-wide association study of 4,533 individuals with celiac disease (cases) and 10,750 control subjects, and genotyped 113 selected SNPs with P(GWAS) < 10(-4) and 18 SNPs from 14 known loci in a further 4,918 cases and 5,684 controls.
Abstract: We performed a second-generation genome-wide association study of 4,533 individuals with celiac disease (cases) and 10,750 control subjects. We genotyped 113 selected SNPs with P(GWAS) < 10(-4) and 18 SNPs from 14 known loci in a further 4,918 cases and 5,684 controls. Variants from 13 new regions reached genome-wide significance (P(combined) < 5 x 10(-8)); most contain genes with immune functions (BACH2, CCR4, CD80, CIITA-SOCS1-CLEC16A, ICOSLG and ZMIZ1), with ETS1, RUNX3, THEMIS and TNFRSF14 having key roles in thymic T-cell selection. There was evidence to suggest associations for a further 13 regions. In an expression quantitative trait meta-analysis of 1,469 whole blood samples, 20 of 38 (52.6%) tested loci had celiac risk variants correlated (P < 0.0028, FDR 5%) with cis gene expression.
894 citations
TL;DR: The literature reviewed provides enough promise for anticipating therapeutic and diagnostic applications of surface-modified nanoparticles, with particular focus on the literature concerning particles other than liposomes.
893 citations
TL;DR: This report from the ISPOR Indirect Treatment Comparisons Good Research Practices Task Force provides guidance on the interpretation of indirect treatment comparisons and network meta-analysis to assist policymakers and health-care professionals in using its findings for decision making.
892 citations
University College London1, University of Cambridge2, University of Cologne3, Leiden University4, Utrecht University5, National Institutes of Health6, University of Pennsylvania7, University of Glasgow8, University of Edinburgh9, Mayo Clinic10, University of London11, University of Bristol12, Cardiff University13, University of Oxford14, University of Ioannina15, University of Hamburg16, Lithuanian University of Health Sciences17, Jagiellonian University18, Russian Academy19, Karolinska Institutet20, Memorial Hospital of South Bend21, University of Groningen22, MedStar Washington Hospital Center23, Swansea University24, Brown University25, University of Iowa26, Harvard University27, University of Exeter28, University of North Carolina at Chapel Hill29, Boston University30, Medical Research Council31, University of California, San Diego32, University of Mississippi33, Fred Hutchinson Cancer Research Center34
TL;DR: IL6R blockade could provide a novel therapeutic approach to prevention of coronary heart disease that warrants testing in suitably powered randomised trials and could help to validate and prioritise novel drug targets or to repurpose existing agents and targets for new therapeutic uses.
891 citations
Authors
Showing all 36692 results
| Name | H-index | Papers | Citations |
|---|---|---|---|
| Ronald C. Kessler | 274 | 1332 | 328983 |
| Nicholas J. Wareham | 212 | 1657 | 204896 |
| André G. Uitterlinden | 199 | 1229 | 156747 |
| Lei Jiang | 170 | 2244 | 135205 |
| Brenda W.J.H. Penninx | 170 | 1139 | 119082 |
| Richard H. Friend | 169 | 1182 | 140032 |
| Panos Deloukas | 162 | 410 | 154018 |
| Jerome I. Rotter | 156 | 1071 | 116296 |
| Christopher M. Dobson | 150 | 1008 | 105475 |
| Dirk Inzé | 149 | 647 | 74468 |
| Scott T. Weiss | 147 | 1025 | 74742 |
| Dieter Lutz | 139 | 671 | 67414 |
| Wilmar B. Schaufeli | 137 | 513 | 95718 |
| Cisca Wijmenga | 136 | 668 | 86572 |
| Arnold B. Bakker | 135 | 506 | 103778 |